Publications

2024

Mackintosh JA, Keir G, Troy LK, Holland AE, Grainge C, Chambers DC, et al. (2024) Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. Respirology. https://doi.org/10.1111/resp.14656

Tikellis G, Corte T, Glaspole IN, Goh NSL, Khor YH, Wrobel J, Symons K, Fuhrmeister L, Glenn L, Chirayath S, Troy LK, King B, Holland AE. (2024) Navigating the COVID-19 pandemic: Experiences and self-management approaches adopted by people with interstitial lung disease. Chron Respir Dis. 21:14799731231226236. doi: 10.1177/14799731231226236.

2023

Lee JYT, Tikellis G, Dowman L, Jones AW, Hoffman M, Mellerick CR, Malaguti C, Khor YH, Holland AE. (2023) Self-management interventions for people with pulmonary fibrosis: a scoping review. Eur Respir Rev. 32(170):230092. doi: 10.1183/16000617.0092-2023.

Tikellis G, Hoffman M, Mellerick C, Burge AT, Holland AE. (2023) Barriers to and facilitators of the use of oxygen therapy in people living with an interstitial lung disease: a systematic review of qualitative evidence. Eur Respir Rev. 32(169):230066. doi: 10.1183/16000617.0066-2023

Gaikwad AV, Lu W....Eapen MS, Sohal SS (2023) Endothelial-to-mesenchymal transition: a precursor to pulmonary arterial remodelling in patients with idiopathic pulmonary fibrosis. ERJ Open Research. 9: 00487-2022; DOI: 10.1183/23120541.00487-2022

Wong AW, Sun H, Cox IA, Fisher JH, Khalil N, Johannson KA, Marcoux V, Assayag D, Manganas H, Kolb M, Palmer AJ, de Graaff B, Walters EH, Hopkins P, Zappala C, Goh NS, Moodley Y, Navaratnam V, Corte TJ, Ryerson CJ, Zhang W. (2023) Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease. PLoS One. 18(3):e0283110. doi: 10.1371/journal.pone.0283110

Barnes H, Chambers D, Grainge C, Corte TJ, Bastiampillai S, Frenkel S, Westall G, Collard H, Glaspole I. (2023) Clinical utility of a standardized chronic hypersensitivity pneumonitis exposure questionnaire. Respirology. 28(4):366-372. doi: 10.1111/resp.14404

Lucas, S.E.M., Raspin, K., Mackintosh, J., I. Glaspole, Reynolds, P.N., Chia, C., Grainge, C., Kendall, P., Troy, L., Schwartz, D.A., Wood-Baker, R., Walsh, S.L.F., Moodley, Y., Robertson, J., Macansh, S., Walters, E.H., Chambers, D., Corte, T.J., Dickinson, J.L. (2023) Preclinical interstitial lung disease in relatives of familial pulmonary fibrosis patients, Pulmonology, 29(3):257-260, https://doi.org/10.1016/j.pulmoe.2022.09.002.

Tikellis, G., Corte, T., Glaspole, I.N. et al. (2023). "Understanding the telehealth experience of care by people with ILD during the COVID-19 pandemic: what have we learnt?" BMC Pulmonary Medicine 23(1): 113.

Barnes H, Humphries SM, George PM, Assayag D, Glaspole I, Mackintosh JA, Corte TJ, (...) Walsh S. (2023) Machine learning in radiology: the new frontier in interstitial lung diseases. Lancet Digit Health. 5(1):e41-e50. doi: 10.1016/S2589-7500(22)00230-8

West A, Chaudhuri N, Barczyk A, Wilsher ML, Hopkins P, Glaspole I, Corte TJ, (...) Montgomery AB. (2023) Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. thorax-2022-219391. doi: 10.1136/thorax-2022-219391

Jee, A.S., Stewart, I., Youssef, P., Adelstein, S., Lai, D., Hua, S., Stevens, W., Proudman, S., Ngian, G.-S., Glaspole, I.N., Moodley, Y.P., Bleasel, J.F., Macansh, S., Nikpour, M., Sahhar, J., Corte, T.J., (2023) A composite serum biomarker index for the diagnosis of systemic sclerosis interstitial lung disease: a multicentre, observational, cohort study. Arthritis Rheumatol. https://doi.org/10.1002/art.42491

Assayag D, Adegunsoye A, Sheehy R, Morisset J, Khalil N, Johannson KA, Marcoux V, Kolb M, Fisher JH, Manganas H, Wrobel J, Wilsher M, De Boer S, Mackintosh J, Chambers DC, Glaspole I, Keir GJ, Lee CT, Jablonski R, Vij R, Strek ME, Corte TJ, Ryerson CJ. (2023) Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia. Chest. 163(5):1156-1165. doi: 10.1016/j.chest.2022.12.039.

Zheng Q, Cox IA, de Graaff B, Campbell JA, Corte TJ, Glaspole I, Navaratnam V, Hopkins P, Zappala C, Ahmad H, Zhao T, Macansh S, Walters EH, Palmer AJ. (2023) The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument. Qual Life Res. 32(6):1609-1619. doi: 10.1007/s11136-022-03331-8

2022

Cox IA, de Graaff B, Ahmed H, Campbell J, Otahal P, Corte TJ, Moodley Y, Goh N, Hopkins P, Macansh S, Walters EH, Palmer AJ. (2022) The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study. Eur J Health Econ. doi: 10.1007/s10198-022-01538-7

Glenn LM, Troy LK, Corte TJ. (2022) Diagnosing interstitial lung disease by multidisciplinary discussion: A review. Front Med 21;9:1017501. doi: 10.3389/fmed.2022.1017501

Cottin V, Selman M, Inoue Y, Wong AW, Corte TJ, (...) Wells AU. (2022) Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. Am J Respir Crit Care Med. 206(4):e7-e41. doi: 10.1164/rccm.202206-1041ST

Cottin V, Tomassetti S, Valenzuela C, Walsh SLF, Antoniou KM, Bonella F, Brown KK, Collard HR, Corte TJ, (...) Ryerson CJ. (2022) Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. Am J Respir Crit Care Med. 206(3):247-259. doi: 10.1164/rccm.202111-2607PP

Molina-Molina M, Kreuter M, Cottin V, Corte TJ, (...) Maher TM. (2022) Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis. Front Med. 17;9:897102. doi: 10.3389/fmed.2022.897102

Seth I, Bhagavata Srinivasan SP, Bulloch G, Yi DS, Frankel A, Hsu K, Passam F, Garsia R, Corte TJ. (2022) Diffuse alveolar haemorrhage as a rare complication of antiphospholipid syndrome. Respirol Case Rep. 10(5):e0948. doi: 10.1002/rcr2.948

Kreuter M, Maher TM, Corte TJ, (...) Cottin V. (2022) Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Adv Ther. 39(2):1081-1095. doi: 10.1007/s12325-021-02009-w

Humphries SM, Mackintosh JA, Jo HE, Walsh SLF, Silva M, Calandriello L, Chapman S, Ellis S, Glaspole I, Goh N, Grainge C, Hopkins PMA, Keir GJ, Moodley Y, Reynolds PN, Walters EH, Baraghoshi D, Wells AU, Lynch DA, Corte TJ. (2022) Quantitative computed tomography predicts outcomes in idiopathic pulmonary fibrosis. Respirology. 27(12):1045-1053. doi: 10.1111/resp.14333.

Holland AE, Glaspole I, (2022) Lockdown as the mother of invention: disruptive technology in a disrupted time, Lancet Respir Med, https://doi.org/10.1016/S2213-2600(22)00291-0

Jaffar J, McMillan L, Wilson N, Panousis C, Hardy C, Cho HJ, Symons K, Glaspole I, Westall G, Wong M. (2022) Coagulation factor-XII induces interleukin-6 by primary lung fibroblasts: a role in idiopathic pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 322(2):L258-L272. doi: 10.1152/ajplung.00165.2021.

Holland AE, (2022) Physiotherapy management of interstitial lung disease. Journal of Physiotherapy, 68(3):158-164. https://doi.org/10.1016/j.jphys.2022.06.006.

Khor YH, Goh NSL, W(...) Ryerson CJ; CARE-PF Investigators. (2022) Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. Ann Am Thorac Soc. 19(6):962-970. doi: 10.1513/AnnalsATS.202108-980OC.

Walsh SL, Mackintosh JA, (...) Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Zappala C, Keir G, Cooper WA, Mahar AM, Ellis S, Wells AU, Corte TJ. (2022 Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-resolution Computed Tomography. Am J Respir Crit Care Med. 206(7):883-891. doi: 10.1164/rccm.202112-2684OC.

Christian K, Hey-Cunningham A, Corte T, Goh N, Jaffar J, Reynolds P, Teoh A, Troy L. (2022) Establishing CREATE: lessons learned in setting up a training environment for early career researchers in respiratory medicine. BMC Medical Education. 22:136 https://doi.org/10.1186/s12909-022-03169-1

Gaikwad A, Wenying Lu W, Dey S, Bhattarai P, Chia C, Larby J, Haug G, Myers S, Jaffar J, Westall, G, (...) Eapen M S, Sohal S S. (2022) Vascular remodelling in IPF patients and its detrimental effect on lung physiology: potential role of endothelial to mesenchymal transition (EndMT).  ERJ Open Research. DOI: 10.1183/23120541.00571-2021

Lu W, Eapen MS, Singhera GK, Markos J, Haug G, Chia C, Larby J, Brake SJ, Westall GP, Jaffar J, (...) Sohal SS. (2022) Angiotensin-Converting Enzyme 2 (ACE2), Transmembrane Peptidase Serine 2 (TMPRSS2), and Furin Expression Increases in the Lungs of Patients with Idiopathic Pulmonary Fibrosis (IPF) and Lymphangioleiomyomatosis (LAM): Implications for SARS-CoV-2 (COVID-19) Infections. Journal of Clinical Medicine. 11(3):777. https://doi.org/10.3390/jcm11030777

Cox IA, Otahal P, de Graaff B, Corte TJ, Moodley Y, Zappala C, Glaspole I, Hopkins P, Macansh S, Walters EH, Palmer AJ. (2022) Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia. Respirology. 27(3):209-216. doi: 10.1111/resp.14194

Zanframundo G, Faghihi-Kashani S, Scirè CA, Bonella F, Corte TJ, et al. (2022) Defining anti-synthetase syndrome: a systematic literature review. Clin Exp Rheumatol. 40(2):309-319

Kreuter M, Maher TM, Corte TJ, Molina-Molina M, Axmann J, Gilberg F, Kirchgaessler KU, Cottin V. (2022) Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Adv Ther. 39(2):1081-1095. doi: 10.1007/s12325-021-02009-w

Hunninghake GM, (...) Corte TJ, et al.; ILA Study Group. (2022) Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative. Chest. 161(2):470-482. doi: 10.1016/j.chest.2021.06.035

Tikellis G, Corte TJ, Teoh AKY, Glaspole IN, Macansh S, Holland AE. (2022) Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia. Respirology. 27(1):76-84. doi: 10.1111/resp.14185

Teoh AKY, Holland AE, Morisset J, Flaherty KR, Wells AU, Walsh SLF, Glaspole I, Wuyts WA, Corte TJ; ILD MDM Delphi Collaborators. (2022) Essential Features of an Interstitial Lung Disease Multidisciplinary Meeting: An International Delphi Survey. Ann Am Thorac Soc. 19(1):66-73. doi: 10.1513/AnnalsATS.202011-1421OC

Clynick B, Corte TJ, (...) Moodley Y. (2022) Biomarker signatures for progressive idiopathic pulmonary fibrosis. Eur Respir J. 59(3):2101181. doi: 10.1183/13993003.01181-2021

Zheng Q, Cox IA, Campbell JA, Xia Q, Otahal P, de Graaff B, Corte TJ, Teoh AKY, Walters EH, Palmer AJ. (2022) Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open Res. 8(1):00591-2021. doi: 10.1183/23120541.00591-2021

2021

Guler, Hur, S. A., Stickland, M. K., Brun, P., Bovet, L., Holland, A. E., et al. (2021). Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax. https://doi.org/10.1136/thoraxjnl-2021-217361

Ryerson CJ, Corte TJ, Myers JL, Walsh SLF, Guler SA. (2021) A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. Eur Respir J. 58(6):2100276. doi: 10.1183/13993003.00276-2021

Corte TJ, Lancaster L, (...) Fischer A. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA₁) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 20218(1):e001026. doi: 10.1136/bmjresp-2021-001026

Polke M, Kondoh Y, Wijsenbeek M, Cottin V, Walsh SLF, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte TJ, et al. (2021) Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Front Med. 8:699644. doi: 10.3389/fmed.2021.699644

Prasad, J., Paul, E., Holland, A. E., Glaspole, I. N., & Westall, G. P. (2021). Physical activity decline is disproportionate to decline in pulmonary physiology in IPF. Respirology. 26(12), 1152–1159. https://doi.org/10.1111/resp.14137

Khor YH, Gutman L, Abu Hussein N, Johannson KA, Glaspole IN, (...) Goh NSL, Ryerson CJ. (2021) Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study. Chest. 160(3):994-1005. doi:10.1016/j.chest.2021.04.037

Khor, YH.  (2021) Pulmonary fibrosis: Where from and where to? Respirology. 1-3. https://doi.org/10.1111/resp.14125

Chambers DC, Apte SH, Deller D, Masel PJ, Jones CM, Newbigin K, Matula M, Rapchuk IL. (2021). Radiologic outcomes of whole lung lavage for artificial stone associated silicosis Respirology. 26(5):501-503. DOI: 10.1111/resp.14018

Lee, J., Tikellis, G., Glaspole, I., Khor, Y. H., Symons, K., & Holland, A. E. (2021). Self-management for pulmonary fibrosis: Insights from people living with the disease and healthcare professionals. Patient Education and Counseling. https://doi.org/10.1016/j.pec.2021.07.005

Glaspole I., Bonella F., Bargagli E., Glassberg M.K., Caro F., Stansen W., Quaresma M., Orsatti L., Bendstrup E. (2021). Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respiratory Research. 22(1).

Jaffar J., Glaspole I., Symons K., Westall G. (2021). Inhibition of NF-κB by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis. Biomedicine and Pharmacotherapy. 138.

Nambiar S., Tan D.B.A., Clynick B., Bong S.H., Rawlinson C., Gummer J., Corte T.J., Glaspole I., Moodley Y.P., Trengove R. (2021). Untargeted metabolomics of human plasma reveal lipid markers unique to chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Proteomics - Clinical Applications. 15 

Mackintosh J.A., Yerkovich S.T., Tan M.E., Samson L., Hopkins P.M.A., Chambers D.C. (2021). Airway Telomere Length in Lung Transplant Recipients. Frontiers in Immunology. 12

McManus B., Knight D. (2021). Long-chain fatty acids are bad in IPF, or are they? Respirology. 26(3)

Prêle CM, Iosifidis T, (...) Knight D and Mutsaers S. (2021). Reduced SOCS1 expression in lung fibroblasts from patients with IPF is not mediated by promoter methylation or miR155. Biomedicines. 9(5):498 doi:10.3390/biomedicines9050498

Sinclair K.A., Yerkovich S.T., Hopkins P.M.-A., Fieuw A.M., Ford P., Powell J.E., O'Sullivan B., Chambers D.C. (2021). The autotaxin-lysophosphatidic acid pathway mediates mesenchymal cell recruitment and fibrotic contraction in lung transplant fibrosis. Journal of Heart and Lung Transplantation 40(1)

Teoh, AKY, Corte, TJ. (2021). Contemporary Concise Review 2020: Interstitial lung disease. Respirology 26: 604– 611. https://doi.org/10.1111/resp.14063

Liu G, Corte T, (...) Hansbro PM. (2021).Therapeutic targets in lung tissue remodelling and fibrosis. Pharmacology and Therapeutics. 

Jee AS, Parker MJS, McGill N, Bleasel JF, Webster S, Troy LK, Corte TJ. (2021) Nailfold capillaroscopy by smartphone-dermatoscope for connective tissue disease diagnosis in interstitial lung disease: a prospective observational study. ERJ Open Res. 7(4):00416-2021. doi: 10.1183/23120541.00416-2021

Kheir, F., Uribe Becerra, J. P., Bissell, B., Ghazipura, M., Herman, D., Hon, S. M., Hossain, T., Khor, Y. H., (...) Wilson, K. C. (2021). Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review. Annals of the American Thoracic Society. https://doi.org/10.1513/AnnalsATS.202102-197OC

Nambiar S, Clynick B, How BS, King A, Walters EH, Goh NS, Corte TJ, Trengove R, Tan D, Moodley Y.  (2021). There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF). Respiratory Research, 22(1),[105]. https://doi.org/10.1186/s12931-021-01682-3

Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database of Systematic Reviews. 2021. (2).

Barnes H., Lu J., Glaspole I., Collard H.R., Johannson K.A. (2021). Exposures and associations with clinical phenotypes in hypersensitivity pneumonitis: A scoping review. Respiratory Medicine 184

Harris E.J.A., Lim K.P., Moodley Y., (...) Brims F.J.H. (2021). Low dose CT detected interstitial lung abnormalities in a population with low asbestos exposure. American Journal of Industrial Medicine 64(7)

Guler S.A., Corte T.J. (2021). Interstitial Lung Disease in 2020: A History of Progress. Clinics in Chest Medicine 42(2).

Khor, Y.H., Dudley, K. A., Herman, D., Jacobs, S. S., Lederer, D. J., Krishnan, J. A., Holland, A. E., Ruminjo, J. K., & Thomson, C. C. (2021). Summary for Clinicians: Clinical Practice Guideline on Home Oxygen Therapy for Adults with Chronic Lung Disease. Annals of the American Thoracic Society. 18(9), 1444–1449. https://doi.org/10.1513/AnnalsATS.202102-165CME

Khor YH, Harrison A, Robinson J, Goh NSL, Glaspole I, McDonald CF. (2021). Moderate resting hypoxaemia in fibrotic interstitial lung disease. European Respiratory Journal. 57(1):2001563.

Nathan S.D., Cottin V., Behr J., Hoeper M.M., Martinez F.J., Corte T.J., (...) Wells A.U. (2021). Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. Journal of Heart and Lung Transplantation 40(6).

Jee AS, Parker MJS, Bleasel JF, Troy LK, Lau EM, Jo HE, Teoh AKY, Adelstein S, Webster S, Corte TJ. (2021) Baseline Characteristics and Survival of an Australian Interstitial Pneumonia with Autoimmune Features Cohort. Respiration. 100(9):853-864. doi: 10.1159/000515396

Mackintosh JA, Glenn L, Barnes H, Dunn E, Bancroft S, Reddy T, Teoh AKY, Troy L, Jo H, Geis M, Glaspole I, Grainge C, Corte T, Chambers DC, Hopkins P. (2021). The benefits of a virtual interstitial lung disease multi-disciplinary meeting in the face of COVID-19. Respirology. https://doi.org/10.1111/resp.14062

Philip J, Collins A, Smallwood N, Chang YK, Mo L, Yang IA, Corte T, McDonald CF, Hui D. (2021). Referral criteria to palliative care for patients with respiratory disease: a systematic review. Eur Respir J.  58(4):2004307. doi: 10.1183/13993003.04307-2020

Proudman SM, Corte TJ. Are serum biomarkers useful in the management of systemic sclerosis-associated interstitial lung disease? Respirology. 2021. 26(5):406-408. doi: 10.1111/resp.14017

Kanjrawi AA, Mathers L, Webster S, Corte TJ, Carey S. (2021). Nutritional status and quality of life in interstitial lung disease: a prospective cohort study. BMC Pulmonary Medicine. 21(1):51. doi: 10.1186/s12890-021-01418-5.

Noth I, Cottin V, Chaudhuri N, Corte TJ, Johannson KA, Wijsenbeek M, Jouneau S, Michael A, Quaresma M, Rohr KB, Russell AM, Stowasser S, Maher TM; INMARK trial investigators. (2021). Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. European Respiratory Journal. doi: 10.1183/13993003.01518-2020

Wageck B, Cox NS, Lee J, Romero L, Holland AE. (2021). Characteristics of pulmonary rehabilitation programs following an exacerbation of chronic obstructive pulmonary disease: a systematic review. Journal of Cardiopulmonary Rehabilitation and Prevention. 41(2):78-87.

McLean AEB, Webster SE, Fry M, Lau EM, Corte P, Torzillo PJ, Troy LK, Jo HE, Geis M, Rhodes JE, Cleary S, Spencer L, Corte TJ. (2021). Priorities and expectations of patients attending a multidisciplinary interstitial lung disease clinic. Respirology. 26(1):80-86. doi: 10.1111/resp.13913. 

Cooper WA, Mahar A, Myers JL, Grainge C, Corte TJ, (...) Troy LK. (2021). Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features: Further Lessons from COLDICE, a Prospective Multi-Center Study. American Journal of Respiratory and Critical Care Medicine. doi: 10.1164/rccm.202009-3688OC. 

Tikellis G, Tong A, Lee JYT, Corte TJ, Hey-Cunningham AJ, Bartlett M, Crawford T, Glaspole I, Price J, Maloney J, Holland AE. (2021). Top 10 research priorities for people living with pulmonary fibrosis, their caregivers, healthcare professionals and researchers. Thorax. doi: 10.1136/thoraxjnl-2020-215731.

Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, Symons K, Spencer LM, Reynolds PN, Chapman S, de Boer S, Reddy T, Holland AE, Chambers DC, Glaspole IN, Jo HE, Bleasel JF, Wrobel JP, Dowman L, Parker MJS, Wilsher ML, Goh NSL, Moodley Y, Keir GJ. (2021). Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand. Respirology. 26(1):23-51. doi: 10.1111/resp.13977. 

Holland A.E., Singh S.J., Casaburi R., (...), American Thoracic Society Assembly on Pulmonary Rehabilitation (2021). Defining modern pulmonary rehabilitation: An official American thoracic society workshop report. Annals of the American Thoracic Society 18(5)

Chambers D.C. (2021). The ongoing quest for a fountain of youth: Cell therapy for pulmonary fibrosis. Respirology 26(2)

Cox N.S., Dal Corso S., Hansen H., McDonald C.F., Hill C.J., Zanaboni P., Alison J.A., O'Halloran P., Macdonald H., Holland A.E. (2021). Telerehabilitation for chronic respiratory disease. Cochrane Database of Systematic Reviews.

Cox I.A., de Graaff B., Ahmed H., Campbell J., Otahal P., Corte T.J., Glaspole I., Moodley Y., Goh N., Macansh S., Walters E.H., Palmer A.J. (2021). The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia. Quality of Life Research.

2020

Xu J, Xu X, Jiang L, Dua Kamal, Hansbro PM, Liu G. (2020). SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respiratory Research. 21(1): 182.

Mehta M, Satija S, Paudel KR, Liu G, Chellappan DK, Hansbro PM, Dua K. (2020). Incipient need of targeting airway remodelling using advanced drug delivery in chronic respiratory diseases. Future Medicinal Chemistry. 12(10):873-875.

Ali MK, Kim RY, Brown AC, (...) Hansbro PM, Horvat JC. (2020). Critical role for iron accumulation in the pathogenesis of fibrotic lung disease. Journal of Pathology. 251(1): 49-62. [IF:5.979].

Khor YH, Ryerson CJ, Landry SA, Howard ME, Churchward TJ, Edwards BA, Hamilton GS, Joosten SA.(2020). Interstitial lung disease and obstructive sleep apnoea. Sleep Medicine Reviews.

Holland AE, Dowman L, Smallwood N. (2020). Patient-reported Outcomes for Clinical Trials in Idiopathic Pulmonary Fibrosis: New Opportunities to Understand How Patients Feel and Function. American Journal of Respiratory and Critical Care Medicine. 202(12):1620-1622. doi: 10.1164/rccm.202007-2775ED. 

Holland AE, Corte T, Chambers DC, Palmer AJ, Ekström MP, Glaspole I, Goh NSL, Hepworth G, Khor YH, Hoffman M, Vlahos R, Sköld M, Dowman L, Troy LK, Prasad JD, Walsh J, McDonald CF. (2020). Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trial. BMJ Open. 10(12):e040798. doi: 10.1136/bmjopen-2020-040798

Holland AE, Malaguti C, Hoffman M, Lahham A, Burge AT, Dowman L, May AK, Bondarenko J, Graco M, Tikellis G, Lee JY, Cox NS. (2020). Home-based or remote exercise testing in chronic respiratory disease, during the COVID-19 pandemic and beyond: A rapid review. Chronic Respiratory Disease. doi: 10.1177/1479973120952418. 

Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. (2020). Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: A systematic review. European Respiratory Review. 29(157):190158.

Khor YH, Holland AE, Goh NSL, Miller BR, Vlahos R, Bozinovski S, Lahham A, Glaspole I, McDonald CF. (2020). Ambulatory oxygen in fibrotic interstitial lung disease: a pilot, randomised, triple-blinded, sham-controlled trial. Chest. 181(1):234-244.

Sweeney DJ, Khor YH*, Goh NSL* (* joint senior authors) (2020). The Unmet Care Needs of Progressive Fibrosing Interstitial Lung Disease. Respirology. 25(12):1231-1232. 

Cox IA, Arriagada NB, de Graaff B, Corte TJ, Glaspole I, Lartey S, Walters EH, Palmer AJ. (2020). Health-related quality of life of patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. European Respiratory Review. 29(158):200154. doi: 10.1183/16000617.0154-2020. 

Martinu T., Koutsokera A., Benden C., Cantu E., Chambers D., (...) Tomlinson G., Bronchoalveolar Lavage Standardization Workgroup. (2020). International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation. Journal of Heart and Lung Transplantation 39(11)

Hoy R.F., Chambers D.C. (2020) Silica-related diseases in the modern world. Allergy: European Journal of Allergy and Clinical Immunology 75(11)

Moore I, Wrobel J, Rhodes J, Lin Q, Webster S, Jo H, Troy L, Grainge C, Glaspole I, Corte TJ, Australasian ILD Registry. (2020) Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database. BMC Pulmonary Medicine. 20(1):257. doi: 10.1186/s12890-020-01297-2. 

Ogger P.P., (...) Chambers D.C., Maher T.M., Lloyd C.M., Byrne A.J. (2020) Itaconate controls the severity of pulmonary fibrosis. Science Immunology 5(52)

Parker MJS, Corte TJ. (2020) First risk, next reward? A new clinico-radiological risk model predicts mortality in rheumatoid arthritis-associated interstitial lung disease. Respirology. (12):1225-1226. doi: 10.1111/resp.13924.

Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA, Chua AT, Corte TJ, (...) Wilson KC. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 202(3):e36-e69. doi: 10.1164/rccm.202005-2032ST.

Ogger P.P., (...) Chambers D.C., Maher T.M., Lloyd C.M., Byrne A.J. (2020). Itaconate controls the severity of pulmonary fibrosis. Science Immunology. 5(52)

Jaffar J, Griffiths K, Oveissi S, Duan M, Foley M, Glaspole I, Symons K, Organ L, Westall G. (2020) CXCR4 + cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis. Respiratory Research. 26;21(1):221. doi: 10.1186/s12931-020-01467-0.

Chambers D.C., Lutzky V.P., Apte S.H., Godbolt D., Feenstra J., Mackintosh J. (2020). Successful treatment of telomeropathy-related interstitial lung disease with immunosuppression and danazol. Respirology Case Reports 8(6).

Hoy R., Chambers D.C. (2020). Silicosis: An ancient disease in need of a dose of modern medicine. Respirology 25(5).

Khoo J.K., Barnes H., Key S., Glaspole I.N., Östör A.J. (2020). Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: Systematic review and meta-analysis. Rheumatology. 59(9). 

Abramson MJ, Murambadoro T, Alif SM, Benke GP, Dharmage SC, Glaspole I, Hopkins P, Hoy RF, Klebe S, Moodley Y, Rawson S, Reynolds PN, Wolfe R, Corte TJ, Walters EH; Australian IPF Registry. (2020). Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study. Thorax. (10):864-869. doi: 10.1136/thoraxjnl-2019-214478. 

Lau EMT, Grainge C, Williamson JP, Corte TJ, Cooper WA, Phillips MJ, Torzillo PJ, Vallely MP, Raghu G, Troy LK. (2020) Methodologies of COLDICE and Cryo-PID studies: details make the difference. Annals of Translational Medicine. 8(12):781. doi: 10.21037/atm-20-3769.

Clynick B, Jo HE, Corte TJ, Glaspole IN, Grainge C, Hopkins PMA, Reynolds PN, Chapman S, Walters EH, (...) Moodley YP. (2020). Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis. European Respiratory Journal. 56(3):1902058. doi: 10.1183/13993003.02058-2019. 

Nambiar S., Bong How S., Gummer J., Trengove R., Moodley Y. (2020). Metabolomics in chronic lung diseases. Respirology 25(2).

Moodley, Y.P., C. Zappala, C. Tedja, et al. Comment on "The natural history of progressive fibrosing interstitial lung diseases". Eur Respir J 2020. 56(6).

Teoh AKY, Corte TJ. (2020). Nonspecific Interstitial Pneumonia. Seminars in Respiratory and Critical Care Medicine. 41(2):184-201. doi: 10.1055/s-0040-1708499. 

Glenn LM, Corte TJ. (2020) Diagnosing idiopathic pulmonary fibrosis: Has the time for surgical lung biopsy passed? Respirology. doi: 10.1111/resp.13909. 

Teoh AKY, Jo HE, Chambers DC, Symons K, Walters EH et al. (2020) Blood monocyte counts as a potential prognostic marker for IPF: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal 55:1901855. doi: 10.1183/13993003.01855-2019.

Tikellis G, Lee JYT, Corte TJ, Maloney J et al. (2020) Peer Connect Service for people with PF in Australia: Participants' experiences and process evaluation. Respirology. doi: 10.1111/resp.13807.

Lee JYT, Tikellis, G, Corte TJ et al. (2020) The supportive care needs of people living with pulmonary fibrosis and their caregivers: A systematic review. European Respiratory Review 20, 29: 190125; doi: 10.1183/16000617.0125-2019.

Teoh AKY, Glaspole I, Macansh S, Corte TJ. (2020). Importance of occupational exposure data: A national idiopathic pulmonary fibrosis registry perspective. American Journal of Respiratory and Critical Care Medicine. 201(9):1165-1167. doi: 10.1164/rccm.201911-2242LE.

Troy LK, Grainge C, Corte TJ, Williamson JP, Vallely MP, Cooper WA et al. Diagnostic accuracy of transbronchial lung cryobiopsy for Interstitial Lung Disease diagnosis (COLDICE): A prospective, comparative study. The Lancet Respiratory Medicine 8(2):171-181. doi: 10.1016/S2213-2600(19)30342-X.

Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T et al. (2020). Acute exacerbation of Idiopathic Pulmonary Fibrosis: International survey and call for harmonisation. European Respiratory Journal, 55(4). doi: 10.1183/13993003.01760-2019.

Barnes H, Morisset J, Molyneaux P, Westall G, Glaspole I, Collard HR; CHP Exposure Assessment Collaborators. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest. 157(6):1506-1512. doi: 10.1016/j.chest.2019.12.018. 

Maher TM, Corte TJ, (...) Cottin V. (2020) Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine. 8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. 

Blokland, K. E. C., Pouwels, S. D., Schuliga, M., Knight, D. A., & Burgess, J. K. (2020). Regulation of cellular senescence by extracellular matrix during chronic fibrotic diseases. Clinical Science, 134(20), 2681-2706.

Schuliga, M., Read, J., Blokland, K. E., Waters, D. W., Burgess, J., Prêle, C., (...) Knight, D. A. (2020). Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner. Clinical Science, 134(7), 889-905.

Blokland, K. E. C., Waters, D. W., Schuliga, M., Read, J., Pouwels, S.D., Grainge, C. L., (...) Knight, D. A. (2020). Senescence of IPF Lung Fibroblasts Disrupt Alveolar Epithelial Cell Proliferation and Promote Migration in Wound Healing. Pharmaceutics, 12(4), [389].

Miles T., Hoyne G.F., Knight D.A., Fear M.W., Mutsaers S.E., Prêle C.M. (2020). The contribution of animal models to understanding the role of the immune system in human idiopathic pulmonary fibrosis. Clinical and Translational Immunology 9(7).

2019

Barnes, H, Goh, NSL, Leong, TL, Hoy, R. Silica-associated lung disease: An old-world exposure in modern industries. Respirology. 2019; 24: 1165– 1175. https://doi.org/10.1111/resp.13695

Walsh J.R., Pegg J., Yerkovich S.T., Morris N., McKeough Z.J., Comans T., Paratz J.D., Chambers D.C. (2019). Longevity of pulmonary rehabilitation benefit for chronic obstructive pulmonary disease-health care utilisation in the subsequent 2 years. BMJ Open Respiratory Research 6(1).

Solomon J.J., Danoff S.K., Goldberg H.J., Woodhead F., Kolb M., Chambers D.C., (...) Rosas I.O., on behalf of the Trail Network. (2019). The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Advances in Therapy. 36(11).

Liu G, (...) Knight DA, Burgess JK, Hansbro PM. (2019). Fibulin-1c regulates transforming growth factor-b activation in pulmonary tissue fibrosis. JCI Insight, 4(16): e124529. 

Khor YH, Goh N, Miller B, Glaspole I, Holland AE, McDonald CF. (2019). A pilot randomised, controlled trial of ambulatory oxygen versus air via portable concentrator in fibrotic interstitial lung disease. American Journal of Respiratory and Critical Care Medicine, 199.

Khor YH, Goh NSL, Miller B, Glaspole I, Holland AE, McDonald CF. (2019). Exertional desaturation and prescription of ambulatory oxygen therapy in ILD. Respiratory Care, 64(3):299-306. doi: 10.4187/respcare.06334.

Burnett K, Glaspole I, Holland AE. (2019). Understanding the patient's experience of care in Idiopathic Pulmonary Fibrosis. Respirology. 24(3):270-277. doi: 10.1111/resp.13414.

Hoffman M, McDonald C, Corte T, Chambers D, Ekstrom M, Glaspole I, Goh N, Holland A. (2019). Effective delivery of ambulatory oxygen in interstitial lung disease - a crossover trial. European Respiratory Journal 54:2. doi: 10.1183/13993003.congress-2019.PA1226.

Holland AE, Lee J, Maloney J, Walsh J. (2019). Sharing experiences and offering mutual support: An evaluation of the Peer Connect Service for people with pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 199:2.

Holland A, Lee J, Maloney J, Walsh J. (2019). Shared experiences, mutual support: Peer Connect Service for Pulmonary Fibrosis. Respirology. 24:33.

Khor YH, Barnes H, Ng Y, Goh N, McDonald CF, Holland AE. (2019). Prognosis of adults with idiopathic pulmonary fibrosis without effective therapies: A systematic review and meta-analysis. American Journal of Respiratory and Critical Care Medicine. 199:2.

Holland A.E., Watson A., Glaspole I. (2019). Comprehensive pulmonary rehabilitation for interstitial lung disease: A consensus approach to identify core education topics. Patient Education and Counseling 102(6)

Glaspole I, Lancaster L, Hernandez P, Inoue Y et al. (2019). Nintedanib in patients with Idiopathic Pulmonary Fibrosis: Safety and tolerability. Respirology, 24:34.

Hatch M, Goh N, Khor Y. (2019). Baseline inflammatory markers and survival in patients with Interstitial lung disease. Respirology 24:167.

Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, (...) Wells AU. (2019). Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine. 7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4.

Jee AS, Corte TJ. (2019). Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs. 79(14):1511-1528. doi: 10.1007/s40265-019-01178-x.

Moodley YP, Corte TJ, Oliver BG, Glaspole IN, Livk A, Ito J, Peters K, Lipscombe R, Casey T, Tan DBA. (2019). Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis. Respirology. 24(11):1111-1114. doi: 10.1111/resp.13668. 

Maher TM, (...) Jenkins RG; INMARK trial investigators. (2019). Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine. 7(9):771-779. doi: 10.1016/S2213-2600(19)30255-3. 

Troy LK, Grainge C, Corte T, (...) Lau EMT; COLDICE Investigator Team. (2019). Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. BMJ Open Respiratory Research. 6(1):e000443. doi: 10.1136/bmjresp-2019-000443.

Noth I, Wijsenbeek M, Kolb M, Bonella F, Moros L, Wachtlin D, Corte TJ. (2019). Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. European Respiratory Journal. 54(3):1801797. doi: 10.1183/13993003.01797-2018.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, .... Corte TJ, (...) Wells AU. (2019). Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

Jee AS, Sahhar J, Youssef P, Bleasel J, Adelstein S, Nguyen M, Corte TJ. (2019). Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons. Pharmacology and Therapeutics. 202:40-52. doi: 10.1016/j.pharmthera.2019.05.014.

Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA; O2 Delphi Collaborators. (2019). Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. European Respiratory Journal. 54(2):1900421. doi: 10.1183/13993003.00421-2019. 

Jo HE, Corte TJ, Glaspole I, Grainge C, Hopkins PMA, Moodley Y, Reynolds PN, (...) Goh NS. (2019). Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. BMC Pulmonary Medicine. 19(1):84. doi: 10.1186/s12890-019-0846-2.

Moore C, (...) Corte TJ, Glaspole I, Prele C, et al. (2019). Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

Culver DA, Behr J, Belperio JA, Corte TJ, (...) Kim HJ. (2019). Patient Registries in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 200(2):160-167. doi: 10.1164/rccm.201902-0431CI.

Troy LK, Young IH, Lau EMT, Wong KKH, Yee BJ, Torzillo PJ, Corte TJ. (2019). Nocturnal hypoxaemia is associated with adverse outcomes in interstitial lung disease. Respirology. 24(10):996-1004. doi: 10.1111/resp.13549. 

Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. (2019). Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns. ERJ Open Research. 5:00118-2019.

Burgess A, Goon K, Brannan JD, Attia J, Palazzi K, Oldmeadow C, Corte TJ, Glaspole I, Goh N, Keir G, Allan H, Chapman S, Cooper W, Ellis S, Hopkins P, Moodley Y, Reynolds P, Zappala C, Macansh S, Grainge C. (2019). Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. Respirology. 24(10):988-995. doi: 10.1111/resp.13540. 

Jo HE, Glaspole I, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, (...) Corte TJ. (2019). Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Respirology. 24(4):361-368. doi: 10.1111/resp.13427. 

Cullmann, K., Blokland, K. E. C., Sebe, A., Schenk, F., Ivics, Z., Heinz, N., & Modlich, U. (2019). Sustained and regulated gene expression by Tet-inducible "all-in-one" retroviral vectors containing the HNRPA2B1-CBX3 UCOE®. Biomaterials, 192, 486-499.

Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Wei, L., Schuliga, M., Jaffar, J., (...) Knight, D. A. (2019). STAT3 Regulates the Onset of Oxidant-induced Senescence in Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 61(1), 61-73.

McVey, M. J., Maishan, M., Blokland, K. E. C., Bartlett, N., & Kuebler, W. M. (2019). Extracellular vesicles in lung health, disease, and therapy. American Journal of Physiology - Lung Cellular and Molecular Physiology, 316(6), L977-L989.

Hoffman M, Augusto VM, Eduardo DS, Silveira BMF, Lemos MD, Parreira VF. (2019). Inspiratory muscle training reduces dyspnea during activities of daily living and improves inspiratory muscle function and quality of life in patients with advanced lung disease. Physiotherapy Theory Practice. 20:1-11

Khor YH, Glaspole I, Goh NSL. (2019). Therapeutic burden in interstitial lung disease: lessons to learn. Respirology. 24(6):566-571. 

Nakazawa A, Dowman LM, Cox NS, McDonald CF, Hill CJ, Lee AL, Holland AE. (2019). Factors predicting progression of exercise training loads in people with interstitial lung disease. European Respiratory Journal Open Research. 5(4). doi: 10.1183/23120541.00245-2018. 

Murtha L.A., (...) Knight D.A., Boyle A.J. (2019). The role of pathological aging in cardiac and pulmonary fibrosis. Aging and Disease 10(2).

Nathan S.D., Costabel U., Glaspole I., Glassberg M.K., Lancaster L.H., Lederer D.J., Pereira C.A., Trzaskoma B., Morgenthien E.A., Limb S.L., Wells A.U. (2019). Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest 155(4).

Wijsenbeek M.S., Holland A.E., Swigris J.J., Renzoni E.A. (2019). Comprehensive supportive care for patients with fibrosing interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 200(2)

Perret J.L., (...) Walters E.H., Abramson M.J., Dharmage S.C. (2019). Residential exposure to outdoor air pollution and post-bronchodilator lung function deficits in mid-adult life. American Journal of Respiratory and Critical Care Medicine 200(1)

Granger C.L., Morris N.R., Holland A.E. (2019). Practical approach to establishing pulmonary rehabilitation for people with non-COPD diagnoses. Respirology 24(9)

Mackintosh J.A., Munsif M., Ranzenbacher L., Thomson C., Musk M., Snell G., Glanville A., Chambers D.C., Hopkins P. (2019). Risk of anastomotic dehiscence in patients with pulmonary fibrosis transplanted while receiving anti-fibrotics: Experience of the Australian Lung Transplant Collaborative. Journal of Heart and Lung Transplantation 38(5)

Moodley Y. (2019). Considerations in the diagnosis of idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 199(5)

Crestani B., Huggins J.T., Kaye M., Costabel U., Glaspole I., Ogura T., Song J.W., Stansen W., Quaresma M., Stowasser S., Kreuter M. (2019). Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. The Lancet Respiratory Medicine 7(1)

Chambers D.C., Carew A.M., Lukowski S.W., Powell J.E. (2019). Transcriptomics and single-cell RNA-sequencing. Respirology 24(1).

Moodley YP, Corte TJ, Oliver BG, Glaspole IN, Livk A, Ito J, Peters K, Lipscombe R, Casey T, Tan DBA. (2019). Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis. Respirology 21(7).

2018

Afzal S., Burge A.T., Lee A.L., Bondarenko J., Holland A.E. (2018). Should the 6-Minute Walk Test Be Stopped If Oxyhemoglobin Saturation Falls Below 80%? Archives of Physical Medicine and Rehabilitation 99(11).

Moodley Y. (2018). An alternative approach to the current diagnostic guidelines for fibrotic interstitial lung disease. Respirology 23(6).

Moodley Y. (2018). A standardized diagnostic ontology for fibrotic interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 197(10).

Cox N.S., McDonald C.F., Alison J.A., (...) Holland A.E. (2018). Telerehabilitation versus traditional centre-based pulmonary rehabilitation for people with chronic respiratory disease: Protocol for a randomised controlled trial. BMC Pulmonary Medicine 18(1).

Barker K., Holland A.E., Lee A.L., Haines T., Ritchie K., Boote C., Saliba J., Lowe S., Pazsa F., Thomas L., Turczyniak M., Skinner E.H. (2018). Multimorbidity rehabilitation versus disease-specific rehabilitation in people with chronic diseases: A pilot randomized controlled trial. Pilot and Feasibility Studies 4(1).

Glaspole I, Wells A, Behr J, Stansen W, Stowasser S, Maher T. (2018). Composite physiologic index in Idiopathic Pulmonary Fibrosis: Effects of nintedanib. Respirology 23:125.

Schuliga M., Grainge C., Westall G., Knight D. (2018). The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. International Journal of Biochemistry and Cell Biology 97.

Barnes H., Holland A.E., Westall G.P., Goh N.S.L., Glaspole I.N. (2018). Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database of Systematic Reviews. 1.

Barnes H, Goh N, Westall G, Holland A, Glaspole I. (2018). Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Respirology. 23:124.

Abramson, MJ, Murumbadoro T, Alif SM, Benke G et al. (2018). Occupational and environmental risk factors for Idiopathic Pulmonary Fibrosis in Australia. European Respiratory Journal. 52. doi: 10.1183/13993003.congress-2018.PA5068.

Schuliga, M., Pechkovsky, D. V., Read, J., Waters, D. W., Blokland, K.E. C., Reid, A. T., (...) Knight, D. A. (2018). Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts. Journal of Cellular and Molecular Medicine, 22(12), 5847-5861.

Waters DW, Blokland KEC, Pathinayake PS, Burgess JK, Mutsaers SE, Prele CM, Schuliga M, Grainge CL, Knight DA. (2018). Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology. doi: 10.1152/ajplung.00037.2018.

Jo HE and Corte TJ. (2018). Idiopathic Pulmonary Fibrosis. Australian Doctor 6 April; 17-24. https://www.howtotreat.com.au/node/47341/1.

Griffiths K, Habiel DM, Jaffar J, Binder U, Darby WG, Hosking CG, Skerra A, Westall GP, Hogaboam CM, Foley M.  (2018). Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis. Scientific Reports. 8: 3212. doi: 10.1038/s41598-018-20811-5.

Koutsakos M, (...) Westall GP, Elliot M, Tangye SG, Wakim LM, Kent SJ, Nguyen THO, Kedzierska K. (2018). Circulating T_FH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. American Association for the Advancement of Science. 10, 428. doi: 10.1126/scitranslmed.aan8405.

Pizzolla A, Nguyen TH, Sant S, Jaffar J, Loudovaris T, Mannering SI, Thomas PG, Westall GP, Kedzierska K, Wakim LM. (2018). Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles. Journal of Clinical Investigations 128 (2):721-733.

Lavender M, Chia KS, Dwyer N, Corte TJ, Spencer L, Thakkar V, McWilliams T, Kotlyar E, Whitford H. (2018). Safe and effective exercise training for patients with pulmonary arterial hypertension: putting current evidence into clinical practice. Expert Review of Respiratory Medicine. 12(11):965-977. doi: 10.1080/17476348.2018.1527687.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V. (2018). Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respiratory Research. 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. 

Cottin V, Castillo D, Poletti V, Kreuter M, Corte TJ, Spagnolo P. (2018). Should Patients With Interstitial Lung Disease Be Seen by Experts? Chest. 154(3):713-714. doi: 10.1016/j.chest.2018.05.044.

Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, (...) Ryerson CJ. (2018). Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration. 96(4):314-322. doi: 10.1159/000489668. 

Jaffar J, Yang SH, Kim SY, Kim HW, Faiz A, Chrzanowski W, Burgess JK. (2018). Greater cellular stiffness in fibroblasts from patients with idiopathic pulmonary fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology. doi: 10.1152/ajplung.00030.2018

Kouranos V, Miranda G, Corte TJ, Renzoni EA. (2018). New treatment paradigms for connective tissue disease-associated interstitial lung disease. Current Opinion Pulmonary Medicine. 24(5):453-460. doi: 10.1097/MCP.0000000000000508

Stewart AG, Keenan C, Langenbach S, Jativa F, Harris T, Schuliga M, Jaffar J, Westall GP, Berhan A, Prodanovic D, Lee PV, Tu Y. (2018). Casein kinase δ/ε inhibitor, PF670462 attenuates the fibrogenic effects of Transforming Growth Factor-β in pulmonary fibrosis. Frontiers in Pharmacology (9):738. doi:10.3389/fphar.2018.00738

Jo HE, Prasad JD, Troy LK, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Holland AE, Lake FR, Keir G, Goh NS, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford HM, Chapman SA, Reynolds PN, Beatson D, (...) Corte TJ. (2018). Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. Medical Journal of Australia. 208(2):82-88. doi: 10.5694/mja17.00799.

Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, Reynolds P, Haydn Walters E, Zappala C, Grainge C, Allan H, Macansh S, Corte TJ. (2018) Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulmonary Medicine. 18(1):19. doi: 10.1186/s12890-018-0575-y.

Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; HP Delphi Collaborators (2018) Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine. 197(8):1036-1044. doi: 10.1164/rccm.201710-1986OC.

Holland AE, Hill CJ, Dowman L, Glaspole I, Goh N, Lee AL, McDonald CF. (2018). Short and long term reliability of the 6-minute walk test in people with idiopathic pulmonary fibrosis. Respiratory Care. 63(8):994-1001.

Yang I.A., Moodley Y. (2018). How do new molecular tools apply to my clinical practice? Respirology 23(11).

Ghavami S., Yeganeh B., Zeki A.A., Shojaei S., Kenyon N.J., Ott S., Samali A., Patterson J., Alizadeh J., Moghadam A.R., Dixon I.M.C., Unruh H., Knight D.A., Post M., Klonisch T., Halayko A.J. (2018). Autophagy and the unfolded protein response promote profibrotic effects of TGF-β1 in human lung fibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology 314(3).

Parker J.M., Glaspole I.N., Lancaster L.H., Haddad T.J., She D., Roseti S.L., Fiening J.P., Grant E.P., Kell C.M., Flaherty K.R. (2018). A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 197(1).

Kolb M, Raghu G, Wells A, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez F for the INSTAGE Investigators (2018). Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Medical Journal 379 (18).

2017

Ryerson C.J., Corte T.J., Lee J.S., Richeldi L., Walsh S.L.F., Myers J.L., Behr J., Cottin V., Danoff S.K., Flaherty K.R., Lederer D.J., Lynch D.A., Martinez F.J., Raghu G., Travis W.D., Udwadia Z., Wells A.U., Collard H.R. (2017). A standardized diagnostic ontology for fibrotic interstitial lung disease an international working group perspective. American Journal of Respiratory and Critical Care Medicine 196(10).

Khor Y.H., McDonald C.F., Hazard A., Symons K., Westall G., Glaspole I., Goh N.S.L., Holland A.E. (2017). Portable oxygen concentrators versus oxygen cylinder during walking in interstitial lung disease: A randomized crossover trial. Respirology 22(8).

Schuliga M, Jaffar J, Berhan A, Langenbach S, Harris T, Waters D, Lee PVS, Grainge C, Westall G, Knight DA and Stewart AG. (2017). Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity. American Journal of Physiology-Lung Cellular and Molecular Physiology. 312:5 L772-L782 doi: 10.1152/ajplung.00553.2016

Schuliga M, Jaffar J, Harris T, Knight DA, Westall G & Stewart AG (2017). The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. Scientific Reports. 7:41770 doi:10.1038/srep41770.

Organ L, Bacci B, Koumoundouros E, Kimpton WG, Samuel CS, Nowell CJ, Bradding P, Roach KM, Westall G, Jaffar J, Snibson KJ. (2017). Inhibition of the KCa3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model. American Journal of Respiratory Cell and Molecular Biology doi: 10.1165/rcmb.2016-0092OC.

Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, Brown CE, Calligaro G, Cassidy N, Corte TJ, (...) Wijsenbeek M. (2017). Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine. 5(12):968-980. doi: 10.1016/S2213-2600(17)30383-1. 

Prasad JD, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Lake F, Hopkins PMA, Corte TJ, Allan H and Glaspole IN. (2017). The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology  22, 1459-1472. doi:10.1111/rep.13163.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, (...) Wells A. (2017). IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. European Respiratory Journal. 50(2):1700936. doi: 10.1183/13993003.00936-2017.

Jee AS, Jo HE, Corte TJ. (2017). Hypersensitivity pneumonitis: A protean and challenging disease. Respirology. 22(8):1489-1490. doi: 10.1111/resp.13158. 

Glaspole I.G, Watson A.L, Allan H, Chapman S, Cooper W.A, Corte T.J, Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y, Reynolds P.N, Ryerson C.J, Walters E.H, Zappala CJ and Holland A.E. (2017). Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. European Respiratory Journal. 50: 1700168.

Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ. (2017). Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology. 22(8):1592-1597. doi: 10.1111/resp.13084. 

Jee AS, Adelstein S, Bleasel J, Keir GJ, Nguyen M, Sahhar J, Youssef P, Corte TJ. (2017). Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF). Journal of Clinical Medicine. 6(5):51. doi: 10.3390/jcm6050051.

Ryerson CJ, Corte TJ, (...) Collard HR. (2017). A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine. 196(10):1249-1254. doi: 10.1164/rccm.201702-0400PP.

Jo HE, Corte TJ. (2017). Nintedanib for idiopathic pulmonary fibrosis in the Japanese population. Respirology. 22(4):630-631. doi: 10.1111/resp.13033. 

Glaspole I.N, Chapman S.A., Cooper W.A., Ellis S.J., Goh N.S., Hopkins P.M, Macansh S., Mahar A., Moodley Y.P., Reynolds P.N., Walters E.H., Zappala C.J. , Corte T.J. (2017). Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology doi: 10.1111/resp.12989 

Khor YH, Goh NS, McDonald CF, Holland AE. (2017). Oxygen therapy for interstitial lung disease: Physicians’ perceptions and experiences. Annals of the American Thoracic Society. 14(12):1772-1778. 

Murtha L.A., Schuliga M.J., Mabotuwana N.S., Hardy S.A., Waters D.W., Burgess J.K., Knight D.A., Boyle A.J. (2017). The processes and mechanisms of cardiac and pulmonary fibrosis. Annals of the American Thoracic Society.

Sohal S.S., Hansbro P.M., Shukla S.D., Eapen M.S., Walters E.H. (2017) Potential Mechanisms of Microbial Pathogens in Idiopathic Interstitial Lung Disease. Chest 152(4).

Jo H.E., Troy L.K., Keir G., Chambers D.C., Holland A., Goh N., Wilsher M., de Boer S., Moodley Y., Grainge C., Whitford H., Chapman S., Reynolds P.N., Glaspole I., Beatson D., Jones L., Hopkins P., Corte T.J. (2017). Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology 22(7).

Bell E.C., Cox N.S., Goh N., Glaspole I., Westall G.P., Watson A., Holland A.E. (2017). RE: Supplemental oxygen and dypsnoea in interstitial lung disease: Absence of evidence is not evidence of absence. European Respiratory Review 26(145).

Dowman L.M., McDonald C.F., Hill C.J., Lee A.L., Barker K., Boote C., Glaspole I., Goh N.S.L., (...) Holland A.E. (2017). The evidence of benefits of exercise training in interstitial lung disease: A randomised controlled trial. Thorax 72(7).

Jee A.S., Corte T.J., Wort S.J., Eves N.D., Wainwright C.E., Piper A. (2017). Year in review 2016: Interstitial lung disease, pulmonary vascular disease, pulmonary function, paediatric lung disease, cystic fibrosis and sleep. Respirology 22(5).

Dowman L.M., (...) Goh N.S.L., Holland A.E. (2017). Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia. Respirology 22(5).

Khor Y.H., Goh N.S.L., McDonald C.F., Holland A.E. (2017). Oxygen therapy for interstitial lung disease a mismatch between patient expectations and experiences. Annals of the American Thoracic Society 14(6).

Schuliga M., Jaffar J., Harris T., Knight D.A., Westall G., Stewart A.G. (2017). The fibrogenic actions of lung fibroblast-derived urokinase: A potential drug target in IPF. Scientific Reports 7.

Alison J.A., (...), Holland A.E., on behalf of the Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. Australian and New Zealand. Pulmonary Rehabilitation Guidelines. Respirology 22(4).

Khor Y.H., Ng Y., Goh N.S.L., Mcdonald C.F., Holland A.E. (2017). Prognosis of adults with idiopathic pulmonary fibrosis without treatment or without effective therapies. Cochrane Database of Systematic Reviews 2017 4.

Nakazawa A., Cox N.S., Holland A.E. (2017). Current best practice in rehabilitation in interstitial lung disease. Therapeutic Advances in Respiratory Disease 11(2).

Bell E.C., Cox N.S., Goh N., Glaspole I., Westall G.P., Watson A., Holland A.E. (2017). Oxygen therapy for interstitial lung disease: A systematic review. European Respiratory Review 26(143).

Murray L.A., Grainge C., Wark P.A., Knight D.A. (2017). Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF. Pharmacology and Therapeutics 169.

Corte T.J., Collard H., Wells A.U. (2017). A new era in idiopathic interstitial pneumonias: Epilogue to a review series. Respirology 22(1).

Murray L.A., (...) Knight D.A., Hogaboam C.M., Herzog E.L. (2017). Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. JCI Insight 2(16).

Beers M.F., Moodley Y. (2017). When is an alveolar type 2 cell an alveolar type 2 cell? A conundrum for lung stem cell biology and regenerative medicine. American Journal of Respiratory Cell and Molecular Biology 57(1).

Jo H.E., Glaspole I., Grainge C., Goh N., Hopkins P.M.A., Moodley Y., Reynolds P.N., (...) Corte T.J. (2017). Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal. 49(3): 1601592. DOI: 10.1183/13993003.01592-2016

Corte T.J., Ryerson C.J., Collard H.R. (2017). Reply: Acute Exacerbation of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 195(4).

Ryerson C.J., Corte T.J., Martinez F.J., Collard H.R. (2017). Reply: The New Idiopathic Pulmonary Fibrosis Acute Exacerbations Document: One Step Ahead but Still Suspended in the Air. American Journal of Respiratory and Critical Care Medicine 195(2).

Nathan S.D., Albera C., Bradford W.Z., Costabel U., Glaspole I., (...) Noble P.W. (2017). Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. The Lancet Respiratory Medicine 5(1).

Habiel D.M., (...) Knight D.A., Hogaboam C.M., Murray L.A. (2017). Divergent roles for Clusterin in Lung Injury and Repair. Scientific Reports 7(1).